{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:20:48Z","timestamp":1787941248270,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03385-2","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:15:07Z","timestamp":1787940907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ticagrelor 60\u00a0mg vs. 90\u00a0mg in elderly ACS patients with vs. without diabetes undergoing percutaneous coronary intervention"],"prefix":"10.1007","author":[{"given":"Angelo","family":"Laino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-9912","authenticated-orcid":false,"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Avvedimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio Dal","family":"Piaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Charlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Di Serafino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"3385_CR1","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN et al (2018) ACC\/AHA versus ESC guidelines on dual antiplatelet therapy. J Am Coll Cardiol 72:2915\u20132931. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14740338.2017.1315101","volume":"16","author":"AS Nathan","year":"2017","unstructured":"Nathan AS, Sen S, Yeh RW (2017) The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf 16:561\u2013572. https:\/\/doi.org\/10.1080\/14740338.2017.1315101","journal-title":"Expert Opin Drug Saf"},{"key":"3385_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","volume":"38","author":"M Valgimigli","year":"2016","unstructured":"Valgimigli M, Costa F, Lokhnygina Y et al (2016) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 38:804\u2013810. https:\/\/doi.org\/10.1093\/eurheartj\/ehw525","journal-title":"Eur Heart J"},{"key":"3385_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","volume":"17","author":"R Piccolo","year":"2021","unstructured":"Piccolo R, Oliva A, Avvedimento M et al (2021) Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention 17:550\u2013560. https:\/\/doi.org\/10.4244\/EIJ-D-20-01197","journal-title":"EuroIntervention"},{"key":"3385_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","volume":"19","author":"D Capodanno","year":"2022","unstructured":"Capodanno D, Bhatt DL, Gibson CM et al (2022) Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol 19:117\u2013132. https:\/\/doi.org\/10.1038\/s41569-021-00598-1","journal-title":"Nat Rev Cardiol"},{"key":"3385_CR6","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44:3720\u20133826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"3385_CR7","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 45:3415\u20133537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"key":"3385_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","volume":"372","author":"GA Roth","year":"2015","unstructured":"Roth GA, Forouzanfar MH, Moran AE et al (2015) Demographic and Epidemiologic drivers of global cardiovascular mortality. N Engl J Med 372:1333\u20131341. https:\/\/doi.org\/10.1056\/NEJMoa1406656","journal-title":"N Engl J Med"},{"key":"3385_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/eurheartj\/ehv698","volume":"37","author":"AW Schoenenberger","year":"2016","unstructured":"Schoenenberger AW, Radovanovic D, Windecker S et al (2016) Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J 37:1304\u20131311. https:\/\/doi.org\/10.1093\/eurheartj\/ehv698","journal-title":"Eur Heart J"},{"key":"3385_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jacc.2010.04.063","volume":"56","author":"D Capodanno","year":"2010","unstructured":"Capodanno D, Angiolillo DJ (2010) Antithrombotic therapy in the elderly. J Am Coll Cardiol 56:1683\u20131692. https:\/\/doi.org\/10.1016\/j.jacc.2010.04.063","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR11","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2337\/dc09-0459","volume":"32","author":"ES Huang","year":"2009","unstructured":"Huang ES, Basu A, O\u2019Grady M et al (2009) Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 32:2225\u20132229. https:\/\/doi.org\/10.2337\/dc09-0459","journal-title":"Diabetes Care"},{"key":"3385_CR12","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","volume":"54","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430\u20132435. https:\/\/doi.org\/10.2337\/diabetes.54.8.2430","journal-title":"Diabetes"},{"key":"3385_CR13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes Mellitus and coronary artery disease. J Am Coll Cardiol 50:1541\u20131547. https:\/\/doi.org\/10.1016\/j.jacc.2007.05.049","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ehjcvp\/pvae054","volume":"10","author":"R Piccolo","year":"2024","unstructured":"Piccolo R, Simonetti F, Avvedimento M et al (2024) Ticagrelor 60 vs. 90\u00a0mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur Heart J Cardiovasc Pharmacother 10:578\u2013587. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae054","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3385_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10557-021-07302-y","volume":"37","author":"R Piccolo","year":"2023","unstructured":"Piccolo R, Avvedimento M, Canonico ME et al (2023) Platelet inhibition with Ticagrelor 60 mg versus 90 mg twice daily in elderly patients with acute coronary syndrome: rationale and design of the PLINY THE ELDER Trial. Cardiovasc Drugs Ther 37:1031\u20131038. https:\/\/doi.org\/10.1007\/s10557-021-07302-y","journal-title":"Cardiovasc Drugs Ther"},{"key":"3385_CR16","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/j.thromres.2010.03.013","volume":"126","author":"SB Mortensen","year":"2010","unstructured":"Mortensen SB, Larsen SB, Grove EL et al (2010) Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 126:e318\u2013e322. https:\/\/doi.org\/10.1016\/j.thromres.2010.03.013","journal-title":"Thromb Res"},{"key":"3385_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","volume":"64","author":"DJ Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Jakubowski JA, Ferreiro JL et al (2014) Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 64:1005\u20131014. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1170","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jcin.2024.12.002","volume":"18","author":"S Cho","year":"2025","unstructured":"Cho S, Jung M, Ahn J-H et al (2025) Diabetic status and thrombogenicity. JACC Cardiovasc Interv 18:720\u2013733. https:\/\/doi.org\/10.1016\/j.jcin.2024.12.002","journal-title":"JACC Cardiovasc Interv"},{"key":"3385_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-015-0232-1","volume":"14","author":"D Alexopoulos","year":"2015","unstructured":"Alexopoulos D, Vogiatzi C, Stavrou K et al (2015) Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. Cardiovasc Diabetol 14:68. https:\/\/doi.org\/10.1186\/s12933-015-0232-1","journal-title":"Cardiovasc Diabetol"},{"key":"3385_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1160\/TH16-09-0703","volume":"117","author":"MR Thomas","year":"2017","unstructured":"Thomas MR, Angiolillo DJ, Bonaca MP et al (2017) Consistent platelet inhibition with ticagrelor 60\u00a0mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost 117:940\u2013947. https:\/\/doi.org\/10.1160\/TH16-09-0703","journal-title":"Thromb Haemost"},{"key":"3385_CR21","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Oestreich JH, Ticagrelor (2014) Pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy: J Hum Pharmacol Drug Therapy 34:1077\u20131090. https:\/\/doi.org\/10.1002\/phar.1477","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"key":"3385_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey RF, Angiolillo DJ, Bonaca MP et al (2016) Platelet inhibition with Ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol 67:1145\u20131154. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.062","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791\u20131800. https:\/\/doi.org\/10.1056\/NEJMoa1500857","journal-title":"N Engl J Med"},{"key":"3385_CR24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T et al (2019) Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med 381:1309\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1908077","journal-title":"N Engl J Med"},{"key":"3385_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ehjcvp\/pvz004","volume":"5","author":"J Kubica","year":"2019","unstructured":"Kubica J, Adamski P, Buszko K et al (2019) Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother 5:139\u2013148. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz004","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3385_CR26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh RW, Secemsky EA, Kereiakes DJ et al (2016) Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315:1735\u20131749. https:\/\/doi.org\/10.1001\/jama.2016.3775","journal-title":"JAMA"},{"key":"3385_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025\u20131034. https:\/\/doi.org\/10.1016\/S0140-6736(17)30397-5","journal-title":"Lancet"},{"key":"3385_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","volume":"151","author":"F Gragnano","year":"2025","unstructured":"Gragnano F, van Klaveren D, Heg D et al (2025) Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention. Circulation 151:343\u2013355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072009","journal-title":"Circulation"},{"key":"3385_CR29","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","volume":"44","author":"D Capodanno","year":"2023","unstructured":"Capodanno D, Angiolillo DJ (2023) Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J 44:3059\u20133072. https:\/\/doi.org\/10.1093\/eurheartj\/ehad362","journal-title":"Eur Heart J"},{"key":"3385_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","volume":"70","author":"K Butler","year":"2010","unstructured":"Butler K, Teng R (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 70:65\u201377. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03669.x","journal-title":"Br J Clin Pharmacol"},{"key":"3385_CR31","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. Circulation 120:2577\u20132585. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.912550","journal-title":"Circulation"},{"key":"3385_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bcp.13812","volume":"85","author":"M \u00c5strand","year":"2019","unstructured":"\u00c5strand M, Amilon C, R\u00f6shammar D et al (2019) Pharmacokinetic\u2013pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol 85:413\u2013421. https:\/\/doi.org\/10.1111\/bcp.13812","journal-title":"Br J Clin Pharmacol"},{"key":"3385_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.thromres.2008.03.023","volume":"123","author":"HL Nielsen","year":"2008","unstructured":"Nielsen HL, Kristensen SD, Thygesen SS et al (2008) Aspirin response evaluated by the VerifyNow\u2122 Aspirin System and Light Transmission Aggregometry. Thromb Res 123:267\u2013273. https:\/\/doi.org\/10.1016\/j.thromres.2008.03.023","journal-title":"Thromb Res"},{"key":"3385_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","volume":"9","author":"PCJ Armstrong","year":"2011","unstructured":"Armstrong PCJ, Leadbeater PD, Chan MV et al (2011) In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 9:552\u2013561. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04160.x","journal-title":"J Thromb Haemost"},{"key":"3385_CR35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","volume":"9","author":"NS Kirkby","year":"2011","unstructured":"Kirkby NS, Leadbeater PDM, Chan MV et al (2011) Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 9:2103\u20132105. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04453.x","journal-title":"J Thromb Haemost"},{"key":"3385_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","volume":"48","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Bernardo E, Ram\u00edrez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes Mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298\u2013304. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.038","journal-title":"J Am Coll Cardiol"},{"key":"3385_CR37","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1074\/jbc.M305474200","volume":"279","author":"IA Ferreira","year":"2004","unstructured":"Ferreira IA, Eybrechts KL, Mocking AIM et al (2004) IRS-1 Mediates inhibition of Ca2\u2009+\u2009mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 279:3254\u20133264. https:\/\/doi.org\/10.1074\/jbc.M305474200","journal-title":"J Biol Chem"},{"key":"3385_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","volume":"24","author":"MA GAGLIA","year":"2011","unstructured":"GAGLIA MA, TORGUSON R, PAKALA R et al (2011) Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 24:529\u2013534. https:\/\/doi.org\/10.1111\/j.1540-8183.2011.00670.x","journal-title":"J Interv Cardiol"},{"key":"3385_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","volume":"3","author":"MJA Vries","year":"2017","unstructured":"Vries MJA, Bouman HJ, Olie RH et al (2017) Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother 3:11\u201317. https:\/\/doi.org\/10.1093\/ehjcvp\/pvw026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3385_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09537104.2020.1754378","volume":"32","author":"A-M Hulshof","year":"2021","unstructured":"Hulshof A-M, Vries M, Verhezen P et al (2021) The influence of prostaglandin E1 and use of inhibitor percentage on the correlation between the multiplate and VerifyNow in patients on dual antiplatelet therapy. Platelets 32:463\u2013468. https:\/\/doi.org\/10.1080\/09537104.2020.1754378","journal-title":"Platelets"},{"key":"3385_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11239-025-03206-y","volume":"59","author":"R Piccolo","year":"2025","unstructured":"Piccolo R, Laino A, Vitale AP et al (2025) Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60\u00a0mg vs. 90\u00a0mg. J Thromb Thrombolysis 59:551\u2013563. https:\/\/doi.org\/10.1007\/s11239-025-03206-y","journal-title":"J Thromb Thrombolysis"},{"key":"3385_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-020-02170-z","volume":"51","author":"DA Gorog","year":"2021","unstructured":"Gorog DA, Becker RC (2021) Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. J Thromb Thrombolysis 51:1\u201311. https:\/\/doi.org\/10.1007\/s11239-020-02170-z","journal-title":"J Thromb Thrombolysis"},{"key":"3385_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1160\/TH07-09-0575","volume":"99","author":"JA Jakubowski","year":"2008","unstructured":"Jakubowski JA, Payne CD, Li YG et al (2008) The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 99:409\u2013415. https:\/\/doi.org\/10.1160\/TH07-09-0575","journal-title":"Thromb Haemost"},{"key":"3385_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/FJC.0b013e3181dd0ec2","volume":"56","author":"JA Jakubowski","year":"2010","unstructured":"Jakubowski JA, Li YG, Small DS et al (2010) A comparison of the VerifyNow P2Y12 Point-of-Care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 56:29\u201337. https:\/\/doi.org\/10.1097\/FJC.0b013e3181dd0ec2","journal-title":"J Cardiovasc Pharmacol"},{"key":"3385_CR45","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/jth.12376","volume":"11","author":"N Kakouros","year":"2013","unstructured":"Kakouros N, Kickler TS, Laws KM et al (2013) Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 11:1814\u20131822. https:\/\/doi.org\/10.1111\/jth.12376","journal-title":"J Thromb Haemost"},{"key":"3385_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1055\/s-0029-1220324","volume":"35","author":"M Cattaneo","year":"2009","unstructured":"Cattaneo M (2009) Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35:158\u2013167. https:\/\/doi.org\/10.1055\/s-0029-1220324","journal-title":"Semin Thromb Hemost"},{"key":"3385_CR47","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","volume":"138","author":"RC Orme","year":"2018","unstructured":"Orme RC, Parker WAE, Thomas MR et al (2018) Study of two dose Regimens of Ticagrelor compared with Clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease. Circulation 138:1290\u20131300. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034790","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03385-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03385-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03385-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:15:08Z","timestamp":1787940908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03385-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":47,"alternative-id":["3385"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03385-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}